Clinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
entrez:
9
6
2022
pubmed:
10
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Investment in workplace wellness programs is increasing despite concerns about lack of clinical benefit and return on investment (ROI). In contrast, outcomes from workplace mental health programs, which treat mental health difficulties more directly, remain mostly unknown. To determine whether participation in an employer-sponsored mental health benefit was associated with improvements in depression and anxiety, workplace productivity, and ROI as well as to examine factors associated with clinical improvement. This cohort study included participants in a US workplace mental health program implemented by 66 employers across 40 states from January 1, 2018, to January 1, 2021. Participants were employees who enrolled in the mental health benefit program and had at least moderate anxiety or depression, at least 1 appointment, and at least 2 outcome assessments. A digital platform that screened individuals for common mental health conditions and provided access to self-guided digital content, care navigation, and video and in-person psychotherapy and/or medication management. Primary outcomes were the Patient Health Questionnaire-9 for depression (range, 0-27) score and the Generalized Anxiety Disorder 7-item scale (range, 0-21) score. The ROI was calculated by comparing the cost of treatment to salary costs for time out of the workplace due to mental health symptoms, measured with the Sheehan Disability Scale. Data were collected through 6 months of follow-up and analyzed using mixed-effects regression. A total of 1132 participants (520 of 724 who reported gender [71.8%] were female; mean [SD] age, 32.9 [8.8] years) were included. Participants reported improvements from pretreatment to posttreatment in depression (b = -6.34; 95% CI, -6.76 to -5.91; Cohen d = -1.11; 95% CI, -1.18 to -1.03) and anxiety (b = -6.28; 95% CI, -6.77 to -5.91; Cohen d = -1.21; 95% CI, -1.30 to -1.13). Symptom change per log-day of treatment was similar post-COVID-19 vs pre-COVID-19 for depression (b = 0.14; 95% CI, -0.10 to 0.38) and anxiety (b = 0.08; 95% CI, -0.22 to 0.38). Workplace salary savings at 6 months at the federal median wage was US $3440 (95% CI, $2730-$4151) with positive ROI across all wage groups. Results of this cohort study suggest that an employer-sponsored workplace mental health program was associated with large clinical effect sizes for employees and positive financial ROI for employers.
Identifiants
pubmed: 35679044
pii: 2793174
doi: 10.1001/jamanetworkopen.2022.16349
pmc: PMC9185188
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2216349Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Références
Int J Occup Environ Med. 2016 Jan;7(1):1-14
pubmed: 26772593
Q J Econ. 2019 Nov;134(4):1747-1791
pubmed: 31564754
JAMA Psychiatry. 2020 Jul 1;77(7):694-702
pubmed: 32186668
Lancet Psychiatry. 2017 Nov;4(11):850-858
pubmed: 29031935
Lancet Psychiatry. 2016 May;3(5):415-24
pubmed: 27083119
Int J Psychiatry Med. 1997;27(2):93-105
pubmed: 9565717
JAMA. 2017 Apr 18;317(15):1517
pubmed: 28418490
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
JAMA. 2003 Jun 18;289(23):3095-105
pubmed: 12813115
Annu Rev Public Health. 2008;29:303-23
pubmed: 18173386
JAMA. 2010 Jan 6;303(1):47-53
pubmed: 20051569
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
JAMA. 2007 Sep 26;298(12):1401-11
pubmed: 17895456
Annu Rev Clin Psychol. 2017 May 8;13:73-98
pubmed: 28375723
Gen Hosp Psychiatry. 2016 Mar-Apr;39:24-31
pubmed: 26719105
J Affect Disord. 2014 Apr;159:118-26
pubmed: 24679399
J Consult Clin Psychol. 1991 Feb;59(1):12-9
pubmed: 2002127
Lancet Psychiatry. 2016 Mar;3(3):243-50
pubmed: 26803397
JAMA. 2019 Apr 16;321(15):1491-1501
pubmed: 30990549
Am J Health Promot. 2019 Jun;33(5):652-665
pubmed: 31007038
BMC Med. 2014 May 09;12:74
pubmed: 24886246
BMC Psychiatry. 2020 Mar 30;20(1):142
pubmed: 32228541
Front Psychol. 2020 Aug 11;11:1969
pubmed: 32849153
Med Care. 2004 Dec;42(12):1194-201
pubmed: 15550799
J Occup Environ Med. 2019 Oct;61(10):812-817
pubmed: 31425323
Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):345-59
pubmed: 20633738
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
Curr Psychiatry Rep. 2007 Dec;9(6):449-59
pubmed: 18221624
Health Aff (Millwood). 2010 Feb;29(2):304-11
pubmed: 20075081
Cogn Behav Ther. 2020 Jan;49(1):1-21
pubmed: 30760112
Clin Psychol Rev. 2015 Jun;38:39-54
pubmed: 25795293
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):490-494
pubmed: 33793459
PLoS One. 2015 Sep 14;10(9):e0138089
pubmed: 26367270